1.Glutathione peroxidase activity in cell cultures from different regions of human epididymis.
Enrique CASTELLÓN ; Hernán RIOSECO ; Juan ROJAS ; Michel ROYER ; Eduardo SALAS ; Héctor CONTRERAS ; Christian HUIDOBRO
Asian Journal of Andrology 2005;7(1):33-37
AIMTo study the secretory activity and androgen regulation of glutathione peroxidase (GPx) in epithelial cell cultures from human epididymis.
METHODSTissue was obtained from patients undergoing therapeutic orchidectomy for prostatic cancer. Epithelial cell cultures were obtained from the caput, corpus and cauda epididymides. Enzymatic activity was measured in conditioned media by colorimetric methods in absence or presence of 1, 10 or 100 nmol/L testosterone. The effect of 1 micromol/L flutamide was also evaluated.
RESULTSGPx activity was higher in cultures from corpus and cauda than caput epididymidis. The presence of different concentrations of testosterone increase enzyme activity in cell cultures from all epididymal regions. Addition of flutamide reverses the androgen dependent increase of GPx activity.
CONCLUSIONGPx activity is secreted from human epididymal cells in a region dependent manner and is regulated by androgens.
Aged ; Androgen Antagonists ; pharmacology ; Cell Culture Techniques ; Epididymis ; enzymology ; Flutamide ; pharmacology ; Glutathione Peroxidase ; drug effects ; metabolism ; Humans ; Male ; Middle Aged ; Testosterone ; metabolism
2.The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Octavio ORELLANA-SERRADELL ; Daniela HERRERA ; Enrique A CASTELLÓN ; Héctor R CONTRERAS
Asian Journal of Andrology 2019;21(5):460-467
One of the factors promoting tumoral progress is the abnormal activation of the epithelial-mesenchymal transition (EMT) program which has been associated with chemoresistance in tumoral cells. The transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), a key EMT activator, has recently been related to docetaxel resistance, the main chemotherapeutic used in advanced prostate cancer treatment. The mechanisms involved in this protective effect are still unclear. In a previous work, we demonstrated that ZEB1 expression induced an EMT-like phenotype in prostate cancer cell lines. In this work, we used prostate cancer cell lines 22Rv1 and DU145 to study the effect of ZEB1 modulation on docetaxel resistance and its possible mechanisms. The results showed that ZEB1 overexpression conferred to 22Rv1 cell resistance to docetaxel while its silencing made DU145 cells more sensitive to it. Analysis of resistance markers showed no presence of ATP-binding cassette subfamily B member 1 (MDR1) and no changes in breast cancer resistance protein (BCRP) or ATP-binding cassette subfamily C member 10 (MRP7). However, a correlation between ZEB1, multidrug resistance-associated protein 1 (MRP1), and ATP-binding cassette subfamily C member 4 (MRP4) expression was observed. MRP4 inhibition, using MK571, resensitized cells with ZEB1 overexpression to docetaxel treatment. In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. The response to docetaxel in our model seems to be mediated mainly by activation of the apoptotic death program. Our results showed that modulation of MRP4 could be a mediator of ZEB1-related resistance to docetaxel in prostate cancer, making it a possible marker for chemotherapy response in patients who do not express MDR1.
Antineoplastic Agents/therapeutic use*
;
Blotting, Western
;
Cell Line, Tumor
;
Docetaxel/therapeutic use*
;
Drug Resistance, Neoplasm
;
Epithelial-Mesenchymal Transition/drug effects*
;
Gene Silencing
;
Humans
;
Male
;
Prostatic Neoplasms/metabolism*
;
Zinc Finger E-box-Binding Homeobox 1/metabolism*
3.Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer.
Fernanda LÓPEZ-MONCADA ; María José TORRES ; Enrique A CASTELLÓN ; Héctor R CONTRERAS
Asian Journal of Andrology 2019;21(6):557-564
Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein highly expressed in bone tissue that acts as a chemoattractant factor promoting the arrival of prostate cancer (PCa) cells to the bone marrow. However, the contribution of SPARC during the early stages of tumor progression remains unclear. In this study, we show that SPARC is highly expressed in PCa tissues with a higher Gleason score. Through stable knockdown and overexpression of SPARC in PC3 and LNCaP cells, respectively, here we demonstrate that endogenous SPARC induces the epithelial-mesenchymal transition (EMT), decreasing E-cadherin and cytokeratin 18 and increasing N-cadherin and vimentin. Moreover, SPARC induces the expression of EMT regulatory transcription factors Snail family transcriptional repressor 1 (Snail), Snail family transcriptional repressor 2 (Slug), and zinc finger E-box binding homeobox 1 (Zeb1). In addition, SPARC knockdown in PC3 cells decreases migration and invasion in vitro, without modifying cell proliferation. Our results indicate that SPARC might facilitate tumor progression by modifying the cellular phenotype in cancer cells.
Blotting, Western
;
Cell Line, Tumor
;
Epithelial-Mesenchymal Transition
;
Humans
;
Male
;
Neoplasm Grading
;
Neoplasm Invasiveness
;
Osteonectin/metabolism*
;
Prostatic Neoplasms/pathology*
;
Tissue Array Analysis